Boxer Capital Management LLC Lowers Position in KalVista Pharmaceuticals, Inc. $KALV

Boxer Capital Management LLC lessened its holdings in shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 78.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 20,400 shares of the specialty pharmaceutical company’s stock after selling 73,000 shares during the quarter. Boxer Capital Management LLC’s holdings in KalVista Pharmaceuticals were worth $248,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently modified their holdings of KALV. Vanguard Group Inc. increased its position in shares of KalVista Pharmaceuticals by 3.7% in the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock worth $30,464,000 after purchasing an additional 88,720 shares during the last quarter. Emerald Advisers LLC lifted its position in KalVista Pharmaceuticals by 30.2% during the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock valued at $16,458,000 after purchasing an additional 313,205 shares during the last quarter. Schroder Investment Management Group grew its stake in KalVista Pharmaceuticals by 108.7% in the 3rd quarter. Schroder Investment Management Group now owns 1,158,457 shares of the specialty pharmaceutical company’s stock worth $14,145,000 after buying an additional 603,499 shares in the last quarter. Ameriprise Financial Inc. grew its stake in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after buying an additional 905,053 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company’s stock worth $10,642,000 after buying an additional 25,971 shares during the last quarter.

KalVista Pharmaceuticals Price Performance

KALV stock opened at $16.94 on Friday. The firm has a market cap of $856.32 million, a P/E ratio of -4.29 and a beta of -0.35. The firm’s fifty day moving average is $15.76 and its 200 day moving average is $14.28. KalVista Pharmaceuticals, Inc. has a 52 week low of $9.23 and a 52 week high of $19.00. The company has a debt-to-equity ratio of 8.18, a quick ratio of 7.21 and a current ratio of 7.22.

Insider Buying and Selling at KalVista Pharmaceuticals

In other news, insider Nicole Sweeny sold 3,975 shares of the firm’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total transaction of $61,890.75. Following the transaction, the insider directly owned 47,003 shares of the company’s stock, valued at approximately $731,836.71. This trade represents a 7.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Brian Piekos sold 1,767 shares of KalVista Pharmaceuticals stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $15.57, for a total value of $27,512.19. Following the completion of the transaction, the chief financial officer owned 13,762 shares in the company, valued at approximately $214,274.34. This represents a 11.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 33,378 shares of company stock valued at $522,290. Corporate insiders own 4.30% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on KALV shares. HC Wainwright raised their price objective on shares of KalVista Pharmaceuticals from $27.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, January 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Thursday, January 22nd. TD Cowen reissued a “buy” rating on shares of KalVista Pharmaceuticals in a research note on Wednesday, December 3rd. Needham & Company LLC raised their price target on KalVista Pharmaceuticals from $28.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Finally, Wall Street Zen upgraded KalVista Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 6th. Seven analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, KalVista Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $29.40.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.